Recent News
On Nov. 8, 2025 CRISPR presented positive Phase 1 data for CTX310 (ANGPTL3) at the American Heart Association Scientific Sessions and simultaneously published the findings in The New England Journal of Medicine, reporting large, dose-dependent LDL and triglyceride reductions.
Major medical outlets and society summaries highlighted durable, one-time dosing effects and planned Phase 2 work for cardiometabolic indications.
Separately, coverage of CASGEVY/VERTEX’s pediatric data in early December reinforced launch momentum for the hemoglobinopathy franchise that uses CRISPR-derived editing, with regulatory submissions and expanded-age data cited as near-term items to watch.
Technical Analysis
Directional indicators show no established trend: ADX registers 9.77, indicating a low-strength directional environment; this weak trend context reduces the reliability of breakout interpretations and favors consolidation near current levels.
DI+ at 18.92 is decreasing (bearish) while DI- at 18.23 is decreasing (bullish); simultaneous declines in both directional components imply directional pressure has eased, producing short-term directional ambiguity that can magnify responses to clinical headlines.
MACD sits at -0.44 with a peak-and-reversal pattern, a bearish momentum signal; however, the MACD currently sits above its signal line (-0.76), producing a bullish crossover signal that suggests short-lived upside potential against the broader momentum shift.
MRO reads 9.2 and is positive, indicating current price sits above WMDST’s target and therefore a propensity for mean reversion; the rising MRO increases the likelihood of price pullback toward valuation anchors if clinical enthusiasm stalls.
RSI at 47.66 shows prior peak-and-reversal behavior and rests near neutral; this level supports range-bound trading and implies limited immediate momentum to extend strong directional moves absent fresh catalysts.
Price relationships reinforce consolidation: the close at $55.86 sits below the 50-day average ($58.93) and near the 20-day average ($56.22), while the super trend upper at $58.22 and the 200-day average at $51.09 create a tight trading band that frames short-term resistance and support.
Volume elevated to 3.28M versus a 10-day average of 1.63M indicates higher-than-normal attention and liquidity, increasing the potential for pronounced intraperiod moves when clinical or regulatory updates arrive.
Fundamental Analysis
Profitability and earnings: net income of -$106,441,000 and EBIT of -$132,059,000 reflect ongoing negative operating profitability; EPS actual stood at -$1.17 versus an estimate of -$1.29, producing an EPS surprise of +9.30%.
Cash and liquidity: cash and short-term investments total $1,915,710,000 with cash of $286,497,000 and ending operating cash flow of $-99,963,000; the cash ratio reads 16.10 (strong liquidity buffer) and market capitalization equals $5,775,400,677, leaving substantial runway relative to near-term obligations.
Growth profile: YoY revenue growth came in at 346.54% with reported revenue growth of 57.14%; revenue QoQ shows no change. These large YoY gains reflect program and commercial revenue inflection rather than steady-state margins.
R&D and margins: research and development expense of $58,902,000 supports multiple clinical-stage programs, driving negative EBITDA of -$127,626,000 and free cash flow of -$84,708,000; free cash flow yield equals -1.47% and free cash growth shows substantial contraction YoY.
Leverage and returns: total debt stands at $211,024,000 with debt-to-assets at 9.40% and debt-to-equity at 0.11; return on assets equals -4.98% and return on equity equals -5.56%, reflecting continued investment ahead of commercial margin realization.
Valuation metrics and peer context: price-to-book equals 3.01, below the industry peer mean of 6.995 and below the industry peer median of 5.79978. PEG equals 5.65 against an industry peer mean of 0.07934 and a high of 5.39182; forward PE sits negative at -43.95 and trailing PE stands at -52.58. These ratios reflect loss-making status and steep growth expectations embedded in some peer comparators.
WMDST values the stock as under-valued given the combination of a strong cash position, accelerating clinical readouts (notably CTX310), and outsized YoY revenue growth despite current negative earnings and cash flow.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2025-09-30 |
| REPORT DATE: | 2025-11-10 |
| NEXT REPORT DATE: | 2026-02-09 |
| CASH FLOW | Begin Period Cash Flow | $ 205.1 M |
| Operating Cash Flow | $ -99.96 M | |
| Capital Expenditures | $ -74.00 K | |
| Change In Working Capital | $ 10.9 M | |
| Dividends Paid | — | |
| Cash Flow Delta | $ 92.9 M | |
| End Period Cash Flow | $ 298.0 M | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | — | |
| Forward Revenue | — | |
| COSTS | ||
| Cost Of Revenue | $ 57.1 M | |
| Depreciation | $ 4.4 M | |
| Depreciation and Amortization | $ 4.4 M | |
| Research and Development | $ 58.9 M | |
| Total Operating Expenses | $ 132.1 M | |
| PROFITABILITY | ||
| Gross Profit | $ -57.12 M | |
| EBITDA | $ -127.63 M | |
| EBIT | $ -132.06 M | |
| Operating Income | $ -132.06 M | |
| Interest Income | — | |
| Interest Expense | — | |
| Net Interest Income | — | |
| Income Before Tax | $ -105.82 M | |
| Tax Provision | $ 619.0 K | |
| Tax Rate | 8.5 % | |
| Net Income | $ -106.44 M | |
| Net Income From Continuing Operations | $ -106.44 M | |
| EARNINGS | ||
| EPS Estimate | $ -1.29 | |
| EPS Actual | $ -1.17 | |
| EPS Difference | $ 0.12 | |
| EPS Surprise | 9.302 % | |
| Forward EPS | $ -1.12 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | $ 2.2 B | |
| Intangible Assets | — | |
| Net Tangible Assets | $ 1.9 B | |
| Total Current Assets | $ 1.9 B | |
| Cash and Short-Term Investments | $ 1.9 B | |
| Cash | $ 286.5 M | |
| Net Receivables | — | |
| Inventory | — | |
| Long-Term Investments | $ 32.3 M | |
| LIABILITIES | ||
| Accounts Payable | $ 11.8 M | |
| Short-Term Debt | — | |
| Total Current Liabilities | $ 119.0 M | |
| Net Debt | — | |
| Total Debt | $ 211.0 M | |
| Total Liabilities | $ 329.3 M | |
| EQUITY | ||
| Total Equity | $ 1.9 B | |
| Retained Earnings | $ -1.82 B | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | $ 20.41 | |
| Shares Outstanding | 93.873 M | |
| Revenue Per-Share | — | |
| VALUATION | Market Capitalization | $ 5.8 B |
| Enterprise Value | $ 4.1 B | |
| Enterprise Multiple | -31.896 | |
| Enterprise Multiple QoQ | 136.153 % | |
| Enterprise Multiple YoY | 48.279 % | |
| Enterprise Multiple IPRWA | high: 52.77 median: 26.559 mean: 4.025 CRSP: -31.896 low: -80.476 |
|
| EV/R | — | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | 1.172 | |
| Asset To Liability | 6.818 | |
| Debt To Capital | 0.099 | |
| Debt To Assets | 0.094 | |
| Debt To Assets QoQ | -11.465 % | |
| Debt To Assets YoY | 527.789 % | |
| Debt To Assets IPRWA | high: 1.045 mean: 0.214 CRSP: 0.094 median: 0.073 low: 0.0 |
|
| Debt To Equity | 0.11 | |
| Debt To Equity QoQ | -12.525 % | |
| Debt To Equity YoY | 532.625 % | |
| Debt To Equity IPRWA | high: 1.395 mean: 0.193 CRSP: 0.11 median: 0.09 low: -0.869 |
|
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | 3.014 | |
| Price To Book QoQ | 13.602 % | |
| Price To Book YoY | 40.248 % | |
| Price To Book IPRWA | high: 17.968 mean: 6.995 median: 5.8 CRSP: 3.014 low: -8.555 |
|
| Price To Earnings (P/E) | -52.584 | |
| Price To Earnings QoQ | 35.069 % | |
| Price To Earnings YoY | 8.715 % | |
| Price To Earnings IPRWA | high: 56.753 mean: -3.414 median: -10.415 CRSP: -52.584 low: -93.179 |
|
| PE/G Ratio | 5.653 | |
| Price To Sales (P/S) | — | |
| Price To Sales QoQ | — | |
| Price To Sales YoY | — | |
| Price To Sales IPRWA | — | |
| FORWARD MULTIPLES | ||
| Forward P/E | -43.953 | |
| Forward PE/G | 4.725 | |
| Forward P/S | — | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | — | |
| ASSET & SALES | ||
| Asset Turnover Ratio | — | |
| Asset Turnover Ratio QoQ | — | |
| Asset Turnover Ratio YoY | — | |
| Asset Turnover Ratio IPRWA | — | |
| Receivables Turnover | — | |
| Receivables Turnover Ratio QoQ | — | |
| Receivables Turnover Ratio YoY | — | |
| Receivables Turnover Ratio IPRWA | — | |
| Inventory Turnover | — | |
| Inventory Turnover Ratio QoQ | — | |
| Inventory Turnover Ratio YoY | — | |
| Inventory Turnover Ratio IPRWA | — | |
| Days Sales Outstanding (DSO) | — | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | -21.776 | |
| Cash Conversion Cycle Days QoQ | — | |
| Cash Conversion Cycle Days YoY | — | |
| Cash Conversion Cycle Days IPRWA | high: 1241.621 median: 189.366 mean: 188.278 CRSP: -21.776 low: -1809.09 |
|
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | — | |
| CapEx To Revenue | — | |
| CapEx To Depreciation | -0.017 | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | $ 1.9 B | |
| Net Invested Capital | $ 1.9 B | |
| Invested Capital | $ 1.9 B | |
| Net Tangible Assets | $ 1.9 B | |
| Net Working Capital | $ 1.8 B | |
| LIQUIDITY | ||
| Cash Ratio | 16.104 | |
| Current Ratio | 16.217 | |
| Current Ratio QoQ | -2.38 % | |
| Current Ratio YoY | -25.077 % | |
| Current Ratio IPRWA | high: 25.502 CRSP: 16.217 mean: 4.327 median: 3.195 low: 0.02 |
|
| Quick Ratio | — | |
| Quick Ratio QoQ | — | |
| Quick Ratio YoY | — | |
| Quick Ratio IPRWA | — | |
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | -1.653 | |
| Cost Of Debt | 7.635 % | |
| Interest Coverage Ratio | -7.422 | |
| Interest Coverage Ratio QoQ | -42.414 % | |
| Interest Coverage Ratio YoY | 19.912 % | |
| Interest Coverage Ratio IPRWA | high: 815.709 mean: 40.195 median: 4.326 CRSP: -7.422 low: -1538.4 |
|
| Operating Cash Flow Ratio | -0.84 | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | 21.776 | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | 10.622 % | |
| Revenue Growth | 5713.953 % | |
| Revenue Growth QoQ | 0.0 % | |
| Revenue Growth YoY | 34654.291 % | |
| Revenue Growth IPRWA | CRSP: 5713.953 % high: 301.849 % mean: 8.038 % median: 4.118 % low: -259.856 % |
|
| Earnings Growth | -9.302 % | |
| Earnings Growth QoQ | -49.319 % | |
| Earnings Growth YoY | -71.125 % | |
| Earnings Growth IPRWA | high: 162.5 % median: -6.452 % CRSP: -9.302 % mean: -13.189 % low: -198.545 % |
|
| MARGINS | ||
| Gross Margin | — | |
| Gross Margin QoQ | — | |
| Gross Margin YoY | — | |
| Gross Margin IPRWA | — | |
| EBIT Margin | — | |
| EBIT Margin QoQ | — | |
| EBIT Margin YoY | — | |
| EBIT Margin IPRWA | — | |
| Return On Sales (ROS) | — | |
| Return On Sales QoQ | — | |
| Return On Sales YoY | — | |
| Return On Sales IPRWA | — | |
| CASH FLOW | ||
| Free Cash Flow (FCF) | $ -84.71 M | |
| Free Cash Flow Yield | -1.467 % | |
| Free Cash Flow Yield QoQ | -52.074 % | |
| Free Cash Flow Yield YoY | -42.918 % | |
| Free Cash Flow Yield IPRWA | high: 30.655 % median: 0.768 % mean: 0.314 % CRSP: -1.467 % low: -57.887 % |
|
| Free Cash Growth | -39.058 % | |
| Free Cash Growth QoQ | -124.929 % | |
| Free Cash Growth YoY | -446.843 % | |
| Free Cash Growth IPRWA | high: 199.867 % mean: 28.205 % median: 21.696 % CRSP: -39.058 % low: -198.468 % |
|
| Free Cash To Net Income | 0.796 | |
| Cash Flow Margin | — | |
| Cash Flow To Earnings | 0.939 | |
| VALUE & RETURNS | ||
| Economic Value Added | $ 0.04 | |
| Return On Assets (ROA) | -4.98 % | |
| Return On Assets QoQ | -49.904 % | |
| Return On Assets YoY | 33.155 % | |
| Return On Assets IPRWA | high: 30.5 % median: 0.176 % mean: -2.25 % CRSP: -4.98 % low: -66.968 % |
|
| Return On Capital Employed (ROCE) | -6.211 % | |
| Return On Equity (ROE) | -0.056 | |
| Return On Equity QoQ | -54.422 % | |
| Return On Equity YoY | 25.367 % | |
| Return On Equity IPRWA | high: 0.948 median: -0.002 mean: -0.005 CRSP: -0.056 low: -1.385 |
|
| DuPont ROE | — | |
| Return On Invested Capital (ROIC) | -6.307 % | |
| Return On Invested Capital QoQ | -48.569 % | |
| Return On Invested Capital YoY | -219.045 % | |
| Return On Invested Capital IPRWA | high: 31.965 % median: 4.232 % mean: -0.046 % CRSP: -6.307 % low: -73.241 % |
|